The company is a specialty biopharmaceutical company that develops therapeutics for the treatment of chronic pain. The company’s drug development platform focuses on the production of small molecule therapeutics that inhibit the bioactive protein Nitric Oxide Synthase (nNOS), which has been shown to modulate pain and cause central nervous system neuronal sensitization. The company’s lead small molecule nNOS inhibitor is currently in phase II clinical trials and is indicated for use in migraines, a condition affecting 35 million North Americans with a market of $17 billion. The company also has drugs in preclinical stage to treat inflammatory pain and neuropathic pain.